-
Mashup Score: 0Ruxolitinib Shows Benefit for Certain Patients with Polycythemia Vera - 10 month(s) ago
Results from the phase 2 MAJIC-PV study showed that patients with polycythemia vera who are intolerant to hydroxycarbamide chemotherapy had superior efficacy results on ruxolitinib.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0JAK Inhibitor Ruxolitinib CRUX Safety and Feasibility Trial - 11 month(s) ago
Dr. David Peereboom from Cleveland Clinic conducted a phase one clinical trial called CRUX to investigate the efficacy and safety of ruxolitinib, an inhibitor of the JAK/STAT pathway, in treating high-grade glioma patients. The JAK/STAT pathway, when dysregulated, promotes the growth of various cancer cells, includi…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🌟 ASCO 2023 🌟 OncologyTube interview with Dr. #DavidPeereboom at @CleClinicMD, on the #CRUX clinical trial at #ASCO23. The study explores the potential of #ruxolitinib in treating high-grade gliomas. 🧠💪 #BrainCancer 🔗 https://t.co/9Ht1v7huSy https://t.co/371IApCi08
-
-
Mashup Score: 0Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids - Full Text View - ClinicalTrials.gov - 11 month(s) ago
Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids – Full Text View.
Source: clinicaltrials.govCategories: Hematologists1, Latest HeadlinesTweet-
To that hopeful end, uhCG/EGF + #ruxolitinib + steroid dose de-escalation study for LGI GVHD just opened! Looking forward to bringing a few additional centers on board: https://t.co/ODDGPenkS5
-
-
Mashup Score: 0Ruxolitinib Safety and Feasibility in NHGGs: Final Toxicity Report - 11 month(s) ago
The results of the CRUX study, which focused on the safety and feasibility of the JAK stat inhibitor Ruxolitinib in newly diagnosed high-grade glioma patients, discussed by Dr. Manmeet Ahluwalia, were presented at ASCO 2023. High-grade gliomas, particularly those with unmethylated MGMT, have poor outcomes despite ad…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🚀 ASCO 2023 🚀 New on OncologyTube. 📄🔬 The CRUX Trial discussed by @BrainTumorDoc Dr. Ahluwalia, from @baptisthealthSF 🙌💪 Check out the interview here: https://t.co/OtxcF0DSfw 📌 #Ruxolitinib #CRUXTrial #HGGs #ASCO23 https://t.co/5cRpmkLuhl
-
-
Mashup Score: 0Ibrutinib EQULIBRIUM Trial: Final Trial Report in nHGGs - 11 month(s) ago
At the (ASCO) 2023 conference, Dr. Manmeet Singh Ahluwalla discussed, researchers presented the final trial report on a phase 1 study called EQUILIBRIUM. The study investigated the combination of a BTK inhibitor called Ibrutinib, along with Temozolomide and radiation therapy, in patients with newly diagnosed gliobla…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🌟 New From ASCO 2023 🌟 Now on OncologyTube, the EQULIBRIUM trial, has just released its latest findings! 🎉🔬 The EQULIBRIUM Trial discussed by @BrainTumorDoc Dr. Manmeet Ahluwalia 🔗 https://t.co/N8lYsB4V1b @baptisthealthSF #Ruxolitinib #HGGs #ASCO23 https://t.co/7m7sUTcApm
-
-
Mashup Score: 1Toxicity Data From the CRUX Trial of Ruxolitinib in High-Grade Gliomas - 11 month(s) ago
Manmeet Ahluwalia, MD, discusses results from the CRUX trial which were presented during the 2023 American Society of Clinical Oncology Annual Meeting.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Check out this interview with Manmeet Ahluwalia, MD, as he discusses findings from a trial on #ruxolitinib which were presented during #ASCO23. @BaptistHealthSF @BHCancerCare @BrainTumorDoc https://t.co/rRxHitF0a4
-
-
Mashup Score: 0Abbas Looks at the Use of Ruxolitinib and Fedratinib in Myelofibrosis - 11 month(s) ago
In the second part of a live discussion on treating patients with myelofibrosis, Jonathan Abbas, MD, led a talk on the impact of ruxolitinib for these patients and where physicians stand with the use of fedratinib.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Jonathan Abbas, MD, led a talk on the impact of #ruxolitinib for patients with #myelofibrosis. #mpnsm | @TNOncology https://t.co/I5b4ksGh4q
-
-
Mashup Score: 0Early Treatment With Ruxolitinib Induces High Response Rates in SR-aGVHD - 12 month(s) ago
The phase 3 REACH2 trial showed that early treatment with ruxolitinib 10 mg led to higher response rates vs that seen with the best available therapy in patients with grade II-IV steroid-refractory acute graft-vs-host disease.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Higher response rates were observed with #ruxolitinib given at 10 mg twice a day vs best available therapy for patients aged 12 years and older with grade II-IV SR-aGVHD. #Tandem23 https://t.co/071Nt3arrN
-
-
Mashup Score: 0
Researchers are backing further investigation of 60 mg selinexor plus ruxolitinib based on positive phase 1/2 findings presented at the AACR Annual Meeting 2023.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Once-weekly #selinexor 60 mg + #ruxolitinib achieved rapid and deep spleen responses that were sustained and robust symptom improvements in patients with treatment-naïve #myelofibrosis. #AACR2023 #mpnsm | @cityofhope https://t.co/dF1zDtwcQ6
-
-
Mashup Score: 0The JAK Inhibitor Pipeline Builds in Dermatology - 1 year(s) ago
Eight JAK inhibitors are approved by the FDA to treat autoimmune, inflammatory, and allergic conditions.
Source: Dermatology TimesCategories: Dermatology, Latest HeadlinesTweet-
Since the first #FDA approval, #JAKInhibitors have been transforming #dermatology. Starting in 2018 with #ruxolitinib, 4 more JAK inhibitors have been approved, treating #AlopeciaAreata, #psoriasis, #PsoriaticArthritis, and #NonsegmentalVitiligo. https://t.co/m15Rs98DC7
-
Superior responses were seen with #ruxolitinib vs best available therapy in patients with polycythemia vera. #mpnsm https://t.co/M2RF0hQz3B